Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting

  • Y. Z
  • S.V. S
  • A.-K. G
  • et al.
N/ACitations
Citations of this article
3Readers
Mendeley users who have this article in their library.

Abstract

Purpose Three new oral anticoagulants (NOACs) have recently become available in the United Kingdom as an alternative to warfarin in the prevention of stroke and systemic embolism in atrial fibrillation. This study examines the relative cost-effectiveness of dabigatran (BID dosing of 150 mg or 110 mg based on patient age), rivaroxaban, and apixaban from a UK payer perspective.

Cite

CITATION STYLE

APA

Y., Z., S.V., S., A.-K., G., H., N., J., H.-N., & T., S. (2014). Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK Setting. Clinical Therapeutics. Y. Zheng: Excerpta Medica Inc. Retrieved from http://www.elsevier.com/locate/clinthera

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free